Skip to content
Research Article Open access CC BY 4.0

Demographics and Overall Survival Pattern of Chronic Myeloid Leukemia in a Tertiary Hospital in South-South Nigeria: The Calabar Experience

Akaba Kingsley, Marcus Inyama, Anthony Kokelu, Olukayode Oshatuyi

Annual Research & Review in Biology · pp. 43–49 · Published 7 Nov 2022

10.9734/arrb/2022/v37i1130546

Abstract

Background: Chronic myeloid leukemia (CML) is a bi- or triphasic disease comprising of the chronic phase (present at diagnosis in approximately 85% of patients) which can easily be controlled with conventional chemotherapy, followed by unstable accelerated phase and terminating in a blastic phase. The treatment of CML has evolved over the years The availability of the tyrosine kinase inhibitors has distinctly changed the disease course for patients with Ph+ and/or BCR-ABL1+  (CML). This study aims to determine the demographics and overall survival patterns of CML patients in the University of Calabar Teaching Hospital (UCTH)l. Methods: The study is a retrospective study of twenty-two (22) CML patients seen and managed at the UCTH from June 2014 to August 2021. Male/female distribution was 9/13, with a median age of 42 years. Overall survival (OS) and progression free survival (PFS) were determined using the Kaplan-Meier techniques. The data were analyzed using Microsoft Excel 2016 and IBM SPSS version 21. Results: Total of 22 CML patients were seen over the 8-year-period of review. The mean age was 42.63, median age 42, and modal age was 37 years respectively. There were 9 males and 13 females. 20 of the patients were in the chronic phase while 2 were in the terminating blastic phase. The presence of mutation was seen in two patients while the remaining 20 showed no mutation. Of the patients, 6 were dead and 16 are alive at the time of review. The overall survival period ranges from 12 to 84 months. The survival distributions for mutation and state of the disease (chronic or blastic) were not statistically significantly different, X2= 3.204, p = 0.073. Conclusion: There is inconsistency in the demographic and overall survival pattern of chronic myeloid leukaemia in our environment. Further study is needed to identify the factors which can help to improve the overall survival pattern in our environment.

CML survival pattern demographic pattern Calabar

References (15)

  1. 1 Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome [DOI]
  2. 2 Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network [DOI]
  3. 3 Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience [DOI]
  4. 4 Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment [DOI]
  5. 5 Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry [DOI]
  6. 6 Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort [DOI]
  7. 7 Chronic Myeloid Leukemia [DOI]
  8. 8 Trends in adult leukemia incidence and survival in Denmark, 1943–2003 [DOI]
  9. 9 Chronic Myeloid Leukemia in Nigerian Patients: Anemia is an Independent Predictor of Overall Survival [DOI]
  10. 10 Epidemiological Pattern of Adult Haematological Malignancies in a Tertiary Hospital in Cross River State
  11. 11 Distribution Pattern and Prevalence of Haematological Cancers among Adults in Abakaliki, South-Eastern Nigeria [DOI]
  12. 12 The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire [DOI]
  13. 13 Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia [DOI]
  14. 14 SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA [DOI]
  15. 15 Prevalence and Treatment of Chronic Lymphocytic Leukaemia (Cll) In Germany: An Analysis of Sickness Funds [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

26

Page views

0

PDF downloads

2

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.